Base de dados : LILACS
Pesquisa : E02.319.267.120.505 [Categoria DeCS]
Referências encontradas : 61 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 7 ir para página                  

  1 / 61 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-796874
Autor: Dias, Queila Cristina; Nunes, Iseu da Silva; Garcia, Patrick Vianna; Fávaro, Wagner José.
Título: Potential therapeutic strategies for non - muscle invasive bladder cancer based on association of intravesical immunotherapy with P-MAPA and systemic administration of cisplatin and doxorubicin
Fonte: Int. braz. j. urol;42(5):942-954, Sept.-Oct. 2016. tab, graf.
Idioma: en.
Projeto: CNPq-Brazil; . FAPESP-Brazil.
Resumo: ABSTRACT The present study describes the histopathological and molecular effects of P-MAPA (Protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride) intravesical immunotherapy combined with systemic doxorubicin or cisplatin for treatment of non-muscle invasive bladder cancer (NMIBC) in an appropriate animal model. Our results showed an undifferentiated tumor, characterizing a tumor invading mucosa or submucosa of the bladder wall (pT1) and papillary carcinoma in situ (pTa) in the Cancer group. The histopathological changes were similar between the combined treatment with intravesical P-MAPA plus systemic Cisplatin and P-MAPA immunotherapy alone, showing decrease of urothelial neoplastic lesions progression and histopathological recovery in 80% of the animals. The animals treated systemically with cisplatin or doxorubicin singly, showed 100% of malignant lesions in the urinary bladder. Furthemore, the combined treatment with P-MAPA and Doxorubicin showed no decrease of urothelial neoplastic lesions progression and histopathological recovery. Furthermore, Akt, PI3K, NF-kB and VEGF protein levels were significantly lower in intravesical P-MAPA plus systemic cisplatin and in intravesical P-MAPA alone treatments than other groups. In contrast, PTEN protein levels were significantly higher in intravesical P-MAPA plus systemic cisplatin and in intravesical P-MAPA alone treatments. Thus, it could be concluded that combination of intravesical P-MAPA immunotherapy and systemic cisplatin in the NMIBC animal model was effective, well tolerated and showed no apparent signs of antagonism between the drugs. In addition, intravesical P-MAPA immunotherapy may be considered as a valuable option for treatment of BCG unresponsive patients that unmet the criteria for early cystectomy.
Descritores: Neoplasias da Bexiga Urinária/terapia
Carcinoma/terapia
Doxorrubicina/uso terapêutico
Cisplatino/uso terapêutico
Imunoterapia/métodos
Proteínas de Membrana/uso terapêutico
Antineoplásicos/uso terapêutico
-Ratos Endogâmicos F344
Neoplasias da Bexiga Urinária/patologia
Administração Intravesical
Vacina BCG
Carcinoma/patologia
Western Blotting
Reprodutibilidade dos Testes
NF-kappa B/análise
Resultado do Tratamento
Terapia Combinada
Progressão da Doença
Fosfatidilinositol 3-Quinases/análise
Modelos Animais
Fator A de Crescimento do Endotélio Vascular/análise
PTEN Fosfo-Hidrolase/análise
Proteínas Proto-Oncogênicas c-akt/análise
Limites: Animais
Feminino
Tipo de Publ: Estudo de Avaliação
Responsável: BR1.1 - BIREME


  2 / 61 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-828944
Autor: Westerman, Mary E; Boorjian, Stephen A; Linder, Brian J.
Título: Safety and efficacy of intravesical alum for intractable hemorrhagic cystitis: a contemporary evaluation
Fonte: Int. braz. j. urol;42(6):1144-1149, Nov.-Dec. 2016. tab.
Idioma: en.
Resumo: ABSTRACT Introduction: Hemorrhagic cystitis (HC) represents a challenging clinical entity. While various intravesical agents have been utilized in this setting, limited data exist regarding safety or efficacy. Herein, then, we evaluated the effectiveness and complications associated with intravesical alum instillation for HC in a contemporary cohort. Materials and Methods: We identified 40 patients treated with intravesical alum for HC between 1997-2014. All patients had failed previous continuous bladder irrigation with normal saline and clot evacuation. Treatment success was defined as requiring no additional therapy beyond normal saline irrigation after alum instillation. Results: Median patient age was 76.5 years (IQR 69, 83). Pelvic radiation was the most common etiology for HC (n=38, 95%). Alum use decreased patient's transfusion requirement, with 82% (32/39) receiving a transfusion within 30 days before alum instillation (median 4 units) versus 59% (23/39) within 30 days after completing alum (median 3 units) (p=0.05). In total, 24 patients (60%) required no additional therapy prior to hospital discharge. Moreover, at a median follow-up of 17 months (IQR 5, 38.5), 13 patients (32.5%) remained without additional treatment for HC. Adverse effects were reported in 15 patients (38%), with bladder spasms representing the most common event (14/40; 35%). No clinical evidence of clinically significant systemic absorption was detected. Conclusion: Intravesical alum therapy is well-tolerated, with resolution of HC in approximately 60% of patients, and a durable response in approximately one-third. Given its favorable safety/efficacy profile, intravesical alum may be considered as a first-line treatment option for patients with HC.
Descritores: Cistite/tratamento farmacológico
Compostos de Alúmen/administração & dosagem
Hemorragia/tratamento farmacológico
-Administração Intravesical
Estudos Retrospectivos
Estudos de Coortes
Resultado do Tratamento
Cistite/complicações
Compostos de Alúmen/efeitos adversos
Alumínio/sangue
Hemorragia/etiologia
Irrigação Terapêutica
Limites: Masculino
Feminino
Idoso
Responsável: BR1.1 - BIREME


  3 / 61 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-892917
Autor: Liu, Zhenbang; Ng, Junxiang; Yuwono, Arianto; Lu, Yadong; Tan, Yung Khan.
Título: Which is best method for instillation of topical therapy to the upper urinary tract? An in vivo porcine study to evaluate three delivery methods
Fonte: Int. braz. j. urol;43(6):1084-1091, Nov.-Dec. 2017. tab, graf.
Idioma: en.
Resumo: ABSTRACT Purpose: To compare the staining intensity of the upper urinary tract (UUT) urothelium among three UUT delivery methods in an in vivo porcine model. Materials and methods: A fluorescent dye solution (indigo carmine) was delivered to the UUT via three different methods: antegrade perfusion, vesico-ureteral reflux via in-dwelling ureteric stent and retrograde perfusion via a 5F open-ended ureteral catheter. Twelve renal units were tested with 4 in each method. After a 2-hour delivery time, the renal-ureter units were harvested en bloc. Time from harvesting to analysis was also standardised to be 2 hours in each arm. Three urothelium samples of the same weight and size were taken from each of the 6 pre-defined points (upper pole, mid pole, lower pole, renal pelvis, mid ureter and distal ureter) and the amount of fluorescence was measured with a spectrometer. Results: The mean fluorescence detected at all 6 predefined points of the UUT urothelium was the highest for the retrograde method. This was statistically significant with p-value less than <0.05 at all 6 points. Conclusions: Retrograde infusion of UUT by an open ended ureteral catheter resulted in highest mean fluorescence detected at all 6 pre-defined points of the UUT urothelium compared to antegrade infusion and vesico-ureteral reflux via indwelling ureteric stents indicating retrograde method ideal for topical therapy throughout the UUT urothelium. More clinical studies are needed to demonstrate if retrograde method could lead to better clinical outcomes compared to the other two methods.
Descritores: Administração Intravesical
Urotélio
Corantes/administração & dosagem
Índigo Carmim/administração & dosagem
-Suínos
Cateterismo Urinário
Modelos Animais
Limites: Animais
Feminino
Tipo de Publ: Estudo Comparativo
Responsável: BR1.1 - BIREME


  4 / 61 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-840799
Autor: Tutolo, Manuela; Ammirati, Enrico; Castagna, Giulia; Klockaerts, Katrien; Plancke, Hendrik; Ost, Dieter; Aa, Frank Van der; Ridder, Dirk De.
Título: A prospective randomized controlled multicentre trial comparing intravesical DMSO and chondroïtin sulphate 2% for painful bladder syndrome/interstitial cystitis
Fonte: Int. braz. j. urol;43(1):134-141, Jan.-Feb. 2017. tab.
Idioma: en.
Resumo: ABSTRACT Objective To compare effectiveness of intravesical chondroïtin sulphate (CS) 2% and dimethyl sulphoxide (DMSO) 50% in patients with painful bladder syndrome/interstitial cystitis (PBS/IC). Materials and methods Patients were randomized to receive either 6 weekly instillations of CS 2% or 50% DMSO. Primary endpoint was difference in proportion of patients achieving score 6 (moderately improved) or 7 (markedly improved) in both groups using the Global Response Assessment (GRA) scale. Secondary parameters were mean 24-hours frequency and nocturia on a 3-day micturition dairy, changes from baseline in O’Leary-Sant questionnaire score and visual analog scale (VAS) for suprapubic pain. Results Thirty-six patients were the intention to treat population (22 in CS and 14 in DMSO group). In DMSO group, 57% withdrew consent and only 6 concluded the trial. Major reasons were pain during and after instillation, intolerable garlic odor and lack of efficacy. In CS group, 27% withdrew consent. Compared with DMSO group, more patients in CS group (72.7% vs. 14%) reported moderate or marked improvement (P=0.002, 95% CI 0.05-0.72) and achieved a reduction in VAS scores (20% vs. 8.3%). CS group performed significantly better in pain reduction (-1.2 vs. -0.6) and nocturia (-2.4 vs. -0.7) and better in total O’Leary reduction (-9.8 vs. -7.2). CS was better tolerated. The trial was stopped due to high number of drop-outs with DMSO. Conclusions Intravesical CS 2% is viable treatment for PBS/IC with minimal side effects. DMSO should be used with caution and with active monitoring of side effects. More randomized controlled studies on intravesical treatments are needed.
Descritores: Dimetil Sulfóxido/administração & dosagem
Sulfatos de Condroitina/administração & dosagem
Cistite Intersticial/tratamento farmacológico
-Fatores de Tempo
Micção
Administração Intravesical
Medição da Dor
Estudos Prospectivos
Inquéritos e Questionários
Reprodutibilidade dos Testes
Resultado do Tratamento
Agentes Urológicos/administração & dosagem
Pessoa de Meia-Idade
Limites: Humanos
Masculino
Feminino
Adolescente
Adulto
Idoso
Adulto Jovem
Responsável: BR1.1 - BIREME


  5 / 61 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-975670
Autor: Ozkan, Tayyar Alp; Yalcin, Mustafa Savas; Dillioglugil, Ozdal; Cevik, Ibrahim.
Título: Encrusted cystitis caused by corynebacterium urealyticum: a case report with novel treatment strategy of intravesical dimethyl sulfoxide
Fonte: Int. braz. j. urol;44(6):1252-1255, Nov.-Dec. 2018. graf.
Idioma: en.
Resumo: ABSTRACT Encrusted cystitis (EC) was first described as chronic cystitis with mucosal calcification in 1914 (1). It is a very rare chronic inflammatory disease presenting with dysuria, pelvic pain and gross hematuria. Voided urine contains mucus or calcified mucopurulent stone like particles. Urinalysis always reveals alkaline pH. It may be present in healthy individuals with no predisposing etiological factors (2-4). Etiologically, previous urological diseases, immunosuppression, urinary infection with urea splitting bacteria, or urological interventions resulting in bladder mucosa trauma may also be present (5, 6). In the present case report, we describe a novel treatment for EC with intravesical dimethyl sulfoxide.
Descritores: Dimetil Sulfóxido/uso terapêutico
Corynebacterium/classificação
Infecções por Corynebacterium/tratamento farmacológico
Cistite/tratamento farmacológico
-Administração Intravesical
Doença Crônica
Resultado do Tratamento
Corynebacterium/isolamento & purificação
Infecções por Corynebacterium/diagnóstico
Infecções por Corynebacterium/microbiologia
Cistite/diagnóstico
Cistite/microbiologia
Limites: Humanos
Masculino
Adulto
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  6 / 61 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-975626
Autor: Sahiner, Ilker Fatih; Soylu, Hakan; Ates, Erhan; Acar, Nuray; Ustunel, Ismail; Danısman, Ahmet.
Título: Impact of intravesical hyaluronic acid treatment on bladder inflammation in interstitial cystitis rat model
Fonte: Int. braz. j. urol;44(5):1014-1022, Sept.-Oct. 2018. tab, graf.
Idioma: en.
Projeto: Akdeniz University Scientific Research Projects.
Resumo: ABSTRACT Objective: To evaluate the effect of intravesical hyaluronic acid (HA) treatment on inflammatory cells and the severity of inflammation in an interstitial cystitis rat model created with hydrogen chloride (HCL) via immunohistochemical studies and myeloperoxidase activity for the first time in the literature. Materials and Methods: A total of 30 adult female white Rattus Norvegicus rats were divided into 3 groups as the HCL group, hyaluronic acid treatment (HCL-HA) group and control group. Chemical cystitis was created by administering HCL(400 microL,10 mM) except control group. A single dose of intravesical HA(0.5 mL,0.8 mg/mL) was administered to the treatment group. The bladder tissues of all subjects were immunohistochemically stained. The cell surface markers were used to evaluate inflammatory cell infiltration. Mast cell activation and IL-6 was evaluated to assess the inflammation and severity of inflammation, respectively. Myeloperoxidase activity was measured as it shows neutrophil density. Statistical significance was accepted as P<0.05. Results: It was observed that there was rich monocyte, T lymphocyte, B lymphocyte, and Natural Killer cells infiltration and high IL-6 levels in the bladder tissue after the intravesical hydrogen chloride instillation, especially in the stroma layer(p<0.005). In the HCL-HA group, severity of inflammation had statistically significantly regressed to the levels of the control group(p<0.005). An increase was observed in the bladder myeloperoxidase activity of the HCL group compared to the other two groups(p<0.05). Conclusions: Single dose intravesical hyluronic acid instillation reduces inflammatory cell infiltration and the severity of bladder inflammation in the rat model of bladder pain syndrome/interstitial cystitis.
Descritores: Bexiga Urinária/efeitos dos fármacos
Cistite Intersticial/tratamento farmacológico
Ácido Hialurônico/uso terapêutico
-Bexiga Urinária/patologia
Índice de Gravidade de Doença
Administração Intravesical
Cistite Intersticial/induzido quimicamente
Cistite Intersticial/patologia
Modelos Animais de Doenças
Ácido Clorídrico
Limites: Animais
Feminino
Ratos
Responsável: BR1.1 - BIREME


  7 / 61 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1154454
Autor: Riccetto, Cássio L. Z.
Título: Editorial Comment: Intravesical injections of platelet-rich plasma is effective and safe in treatment of interstitial cystitis refractory to conventional treatment-A prospective clinical trial
Fonte: Int. braz. j. urol;47(2):456-457, Mar.-Apr. 2021.
Idioma: en.
Descritores: Cistite Intersticial/tratamento farmacológico
Toxinas Botulínicas Tipo A/uso terapêutico
Plasma Rico em Plaquetas
-Administração Intravesical
Estudos Prospectivos
Limites: Humanos
Tipo de Publ: Comentário
Editorial
Responsável: BR1.1 - BIREME


  8 / 61 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1154460
Autor: Korkes, Fernando; Timóteo, Frederico; Ferrari, Karen Linares; Reis, Leonardo Oliveira.
Título: Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer
Fonte: Int. braz. j. urol;47(2):232-236, Mar.-Apr. 2021.
Idioma: en.
Descritores: Neoplasias da Bexiga Urinária/tratamento farmacológico
Vacina BCG/uso terapêutico
-Administração Intravesical
Brasil
Invasividade Neoplásica
Limites: Humanos
Tipo de Publ: Editorial
Responsável: BR1.1 - BIREME


  9 / 61 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-911515
Autor: Majerson , Alejandro; Bassa , Cristóbal; Hurtado, Jennifer; Troncoso , Pablo; Domínguez , Javier.
Título: Antibióticos intravesicales para la prevención de infecciones perioperatorias en trasplante renal / Intravesically applied antibiotics for the prevention of perioperative infections in kidney transplant
Fonte: Rev. chil. urol;83(2):31-34, 2018. graf, tab.
Idioma: es.
Resumo: La enfermedad renal crónica terminal es una enfermedad con gran impacto a nivel económico en los sistemas de salud y en calidad de vida individual. El trasplante renal es el único tratamiento definitivo conocido hasta hoy. La prevalencia de infecciones del tracto urinario (ITU) y bacteriuria asintomática (BA) es mayor que en la población general, alcanzando un 34-43 % durante los primeros años. Además, es frecuente que los microorganismos involucrados sean multirresistentes, describiéndose hasta un 49 por ciento . El uso de antibióticos intra vesicales peri operatorios es controvertido. En nuestro centro, se realizó un ajuste del antibiótico utilizado, basado en las susceptibilidades locales. El objetivo de este trabajo es comparar la incidencia de BA e ITU en pacientes trasplantados, antes y después de ajustar el antibiótico intravesical utilizado, según la resistencia antibiótica local. METODOLOGÍA: Análisis retrospectivo de fichas clínicas y urocultivos de todos los adultos sometidos a trasplante renal entre los años 2013 y 2017 en un centro universitario. Se excluyeron pacientes con trasplante multiorgánico. Se registraron datos de caracterización de la población y datos específicos para los objetivos de este estudio, considerando un plazo de 3 meses desde la cirugía. Se realizó el análisis estadístico con el programa SPSS v. 24.0. RESULTADOS: 110 pacientes cumplieron con los criterios establecidos, de los cuales 61 recibieron profilaxis con cefazolina y 49 con amikacina. Los grupos fueron comparables en cuanto a sexo masculino, edad y días de uso de catéter JJ. En el grupo con cefazolina, un 32 por ciento presentó cultivos positivos, comparado con un 28 por ciento en el grupo con amikacina; esta diferencia no fue estadísticamente significativa. Los microrganismos mes frecuentes fueron E. coli (38,3 por ciento), K. pneumoniae (17 por ciento ), P. aeruginosa (17 por ciento ) y E. cloacae (10,6 por ciento). El 57,4 por ciento de cultivos fueron microorganismos multirresistentes. CONCLUSIÓN: En nuestra serie no se observaron diferencias en la incidencia de cultivos positivos al ajustar el antibiótico intravesical utilizado (AU)

INTRODUCTION: Final-stage chronic kidney disease has great economic impact on health systems and individual quality of life. Kidney transplantation is the only definitive treatment known to date. The prevalence of urinary tract infections (UTI) and asymptomatic bacteriuria (BA) is higher than in the general population, reaching 34-43 pertcent during the first years. In addition, it is common that the microorganisms involved are multiresistant, describing up to 49 pertcent The use of perioperative intra-vesical antibiotics is controversial. In our center, an adjustment to the antibiotic use was made, based on local susceptibilities. The objective of this study is to compare the incidence of BA and UTI in transplant patients, before and after adjusting the intravesical antibiotic used, according to the local antibiotic resistance. METHODOLOGY: Retrospective analysis of clinical records and urine cultures of all adults undergoing kidney transplantation between 2013 and 2017 in a university center. Patients with multiorgan transplantation were excluded. Characterization data of the population and specific data were recorded for the objectives of this study, considering a period of 3 months from the date of surgery. The statistical analysis was performed with the SPSS v. 24.0. RESULTS: 110 patients met the established criteria, of which 61 received prophylaxis with cefazolin and 49 with amikacin. The groups were comparable in terms of male gender, age and days of JJ stent use. In the group with cefazolin, 32 pertcent had positive cultures, compared with 28 pertcent in the group with amikacin. This difference was not statistically significant. The most frequent microorganisms were E. coli (38.3 pertcent ), K. pneumonia (17 pertcent ), P. aeruginosa (17 pertcent ) and E. cloacae (10.6 pertcent ). 57.4 pertcent of cultures were multiresistant microorganisms. CONCLUSION: In our series, no differences were observed in the incidence of positive cultures when adjusting the used intravesical antibiotic (AU)
Descritores: Transplante de Rim
-Infecções Urinárias
Administração Intravesical
Limites: Humanos
Tipo de Publ: Ensaio Clínico
Responsável: CL10.1 - Biblioteca Biomédica


  10 / 61 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1003065
Autor: Almeida, Fernando Gonçalves de; Batezini, Nelson Sivonei da Silva; Simões, Ricardo Santos; Bernardo, Wanderley M.
Título: Interstitial cystitis - intravesical treatment
Fonte: Rev. Assoc. Med. Bras. (1992);65(4):535-540, Apr. 2019.
Idioma: en.
Resumo: The Guidelines Project, an initiative of the Brazilian Medical Association, aims to combine information from the medical field in order to standardize producers to assist the reasoning and decision-making of doctors. The information provided through this project must be assessed and criticized by the physician responsible for the conduct that will be adopted, depending on the conditions and the clinical status of each patient.
Descritores: Cistite Intersticial/tratamento farmacológico
-Poliéster Sulfúrico de Pentosana/uso terapêutico
Administração Intravesical
Brasil
Dimetil Sulfóxido/uso terapêutico
Sulfatos de Condroitina/uso terapêutico
Resultado do Tratamento
Toxinas Botulínicas Tipo A/uso terapêutico
Diterpenos/uso terapêutico
Tomada de Decisão Clínica
Ácido Hialurônico/uso terapêutico
Lidocaína/uso terapêutico
Mycobacterium bovis
Limites: Humanos
Tipo de Publ: Guia de Prática Clínica
Revisão Sistemática
Responsável: BR1.1 - BIREME



página 1 de 7 ir para página                  
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde